Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and Development of Voxvoganan: First-in-Class Synthetic Antimicrobial Peptidomimetic.

Journal of medicinal chemistry·2026
Same author

Biochemical characterization and mutational analysis of the tetrameric DABA transaminase EctB from the Arctic bacterium Marinobacter sp. CK1.

The FEBS journal·2026
Same author

The protein denitrosylase SCoR2 regulates lipogenesis and fat storage.

Science signaling·2025
Same author

Baseline Neuropsychological Characteristics of Adolescents and Young Adults with Down Syndrome Who Participated in Two Clinical Trials of the Drug Memantine.

Brain sciences·2025
Same author

Effectiveness of Exogenous Ketone Salts in Enhancing Circulating Acetoacetate Levels-A Pilot Study in Healthy Adults.

Nutrients·2025
Same author

Antifouling Efficacy on <i>S. epidermidis</i> of Nano-Au Surfaces Functionalized with Polyethylene Glycol (PEG)-Tethered Antimicrobial Peptides.

ACS applied bio materials·2025

Related Experiment Video

Updated: Oct 12, 2025

Immunohistochemical Visualization of Hippocampal Neuron Activity After Spatial Learning in a Mouse Model of Neurodevelopmental Disorders
07:43

Immunohistochemical Visualization of Hippocampal Neuron Activity After Spatial Learning in a Mouse Model of Neurodevelopmental Disorders

Published on: May 12, 2015

11.4K

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome.

Wenche Stensen1,2, Ulli Rothweiler1,2, Richard Alan Engh1

  • 1Department of Chemistry, UiT, The Arctic University of Norway, 9037 Tromsø, Norway.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2021
PubMed
Summary
This summary is machine-generated.

Researchers developed a new DYRK1A inhibitor to address cognitive decline in Down syndrome (DS). This compound is a valuable tool for studying Down syndrome and potential Alzheimer's disease pathology.

Keywords:
DYRK1Adown syndromelearning and memory deficitsmouse modelsneurodegenerationprotein kinase inhibitor

More Related Videos

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells
06:38

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

Published on: March 7, 2025

672
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.4K

Related Experiment Videos

Last Updated: Oct 12, 2025

Immunohistochemical Visualization of Hippocampal Neuron Activity After Spatial Learning in a Mouse Model of Neurodevelopmental Disorders
07:43

Immunohistochemical Visualization of Hippocampal Neuron Activity After Spatial Learning in a Mouse Model of Neurodevelopmental Disorders

Published on: May 12, 2015

11.4K
In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells
06:38

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

Published on: March 7, 2025

672
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.4K

Area of Science:

  • Genetics
  • Neuroscience
  • Pharmacology

Background:

  • Down syndrome (DS) presents significant cognitive challenges, with limited pharmacological treatments available.
  • Individuals with DS experience intellectual disability and early-onset Alzheimer's disease (AD) pathology.
  • Increased life expectancy in DS highlights the need for interventions targeting cognitive deficits.

Purpose of the Study:

  • To introduce a novel inhibitor of the protein kinase DYRK1A.
  • To provide a well-characterized tool compound for Down syndrome research.

Main Methods:

  • Characterization of a novel DYRK1A inhibitor.
  • Evaluation of the inhibitor's utility in mouse models relevant to Down syndrome.

Main Results:

  • A novel inhibitor targeting DYRK1A was successfully developed and characterized.
  • The inhibitor is suitable for use in preclinical mouse models.

Conclusions:

  • The novel DYRK1A inhibitor represents a promising research tool.
  • Further investigation of DYRK1A inhibition may offer therapeutic strategies for cognitive deficits in Down syndrome.